Today
New Haven drug developer Achillion Pharmaceuticals Inc. is preparing clinical testing of a compound that it says could be a promising treatment with other drugs in its stable against the hepatitis C virus (HCV).
Achillion said its ACH-2928 targets the specific genetic protein (NS5A) that HCV needs to replicate itself.
Achillion plans to begin clinical testing of the ACH-2928 compound in combination with other protease inhibitors it is developing to attack HCV, officials said.
Preclinical testing has shown ACH-2928 to be very good at stopping the hepatitis C virus' replication of its RNA, a gene's chemical messenger, said Milind S. Deshpande, Achillion's chief scientific officer. It also hasn't shown any unpleasant side effects or interference with other drugs aimed at arresting HCH.
An estimated 170 million people worldwide -- with three to four million new cases each year -- are infected with hepatitis C, which causes liver inflammation and can lead to cancer of the liver or liver failure.
Source
Also See: Achillion Pharmaceuticals Announces Nomination of NS5A Inhibitor as a Lead Clinical Candidate for Treatment ff HCV
No comments:
Post a Comment